Sensorion Pharma

Sensorion Pharma was founded in 2009 by French and European academics, with the mission of developing therapies for patients with inner ear disorders, such as vertigo and hearing loss. They currently have two drug candidates in clinical trials, for vestibulopathy and sudden sensorineural hearing loss respectively.

Clinical Trials — Recruiting

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Condition: Acute Unilateral Vestibulopathy (AUV)
Intervention: Drug: SENS-111 100mg; Drug: SENS-111 200mg; Drug: Placebo Oral Tablet
Phase: Phase 2; Phase 3

Clinical Trials — Active

A Study of SENS 401 in Healthy Subjects

Condition: Inner Ear Disease
Intervention: Drug: SENS-401; Drug: Placebo
Phase: Phase 1

Clinical Trials — Completed

A Single Dose PK Study of SENS-218 in Healthy Volunteers

Condition: Inner Ear Diseases
Intervention: Drug: SENS-218
Phase: Phase 1


Nothing Found

Sorry, no posts matched your criteria


Sensorion Pharma

Locations: France
Year Founded: 2009
CEO: Laurent Nguyen (MD)